Anatara Lifesciences Ltd
ANR
Company Profile
Business description
Anatara Lifesciences Ltd is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Its products include the Gastrointestinal ReProgramming dietary supplement (GaRP) for humans and Detach for animals. It generates its income from license revenue.
Contact
c/- Perks, 81 Flinders Street
Level 8
AdelaideSA5000
AUST: +61 438027172
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
stocks
ASX small caps offering great value right now
Considering investing in small caps? See our top ASX picks.
stocks
Avoid this overpriced ASX healthcare company
The shares are trading at a 47% premium to our fair value.
stocks
Ask the analyst: Why have Healius shares struggled so much?
Shares in Australia's second biggest pathology operator have floundered in recent years. Shane Ponraj thinks better days could be ahead.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,699.10 | 0.90 | -0.01% |
| CAC 40 | 7,235.11 | 55.86 | 0.78% |
| DAX 40 | 19,626.45 | 200.72 | 1.03% |
| Dow JONES (US) | 44,910.65 | 188.59 | 0.42% |
| FTSE 100 | 8,287.30 | 6.08 | 0.07% |
| HKSE | 19,423.61 | 56.65 | 0.29% |
| NASDAQ | 19,218.17 | 157.69 | 0.83% |
| Nikkei 225 | 38,208.03 | 141.03 | -0.37% |
| NZX 50 Index | 13,066.92 | 13.36 | 0.10% |
| S&P 500 | 6,032.38 | 33.64 | 0.56% |
| S&P/ASX 200 | 8,436.20 | 8.10 | -0.10% |
| SSE Composite Index | 3,326.46 | 30.76 | 0.93% |